Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.840
+0.020 (0.71%)
At close: Aug 17, 2026, 4:00 PM EDT
2.860
+0.020 (0.70%)
Pre-market: Aug 18, 2026, 7:10 AM EDT
Editas Medicine Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Editas Medicine stock has a consensus rating of "Buy" and an average price target of $6.00. The average 1-year stock price forecast is 111.27% higher than the current stock price, while the lowest is $1.00 (-64.79%) and the highest is $15 (+428.17%).
Price Target: $6.00 (+111.27%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Editas Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 6 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 6 | 5 | 5 | 4 | 4 | 4 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 13 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Sell Reiterates n/a | Sell | Reiterates | n/a | n/a | Aug 7, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $4 | Hold | Maintains | $4 | +40.85% | Aug 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $3 → $5 | Buy | Reiterates | $3 → $5 | +76.06% | Aug 6, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 6, 2026 |
| JonesTrading | JonesTrading | Buy Maintains $8 | Buy | Maintains | $8 | +181.69% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
24.59M
from 40.52M
Decreased by -39.31%
Revenue Next Year
19.36M
from 24.59M
Decreased by -21.28%
EPS This Year
-0.83
from -1.80
EPS Next Year
-0.75
from -0.83
EPS and Forward PE are based on non-GAAP adjusted numbers.